EP1009730A1 - Neue derivate des pentaerythrits, deren herstellung und verwendung sowie intermediate zur synthese derselben - Google Patents
Neue derivate des pentaerythrits, deren herstellung und verwendung sowie intermediate zur synthese derselbenInfo
- Publication number
- EP1009730A1 EP1009730A1 EP97945736A EP97945736A EP1009730A1 EP 1009730 A1 EP1009730 A1 EP 1009730A1 EP 97945736 A EP97945736 A EP 97945736A EP 97945736 A EP97945736 A EP 97945736A EP 1009730 A1 EP1009730 A1 EP 1009730A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bis
- compounds according
- nitryloxymethyl
- compounds
- nitryloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000003786 synthesis reaction Methods 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical class OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 title abstract description 14
- 230000015572 biosynthetic process Effects 0.000 title description 8
- 239000000543 intermediate Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 93
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 22
- -1 (nitryloxymethyl) methyl Chemical group 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 claims description 15
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 239000002360 explosive Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 201000001881 impotence Diseases 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- COLPLFZHPXIFCQ-UHFFFAOYSA-N 1,4-dihydropyridine-3,5-dicarboxylic acid Chemical compound OC(=O)C1=CNC=C(C(O)=O)C1 COLPLFZHPXIFCQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- BZXGAYPIKOVVIQ-UHFFFAOYSA-N [3-(benzylamino)-2,2-bis(nitrooxymethyl)-3-oxopropyl] nitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)C(=O)NCC1=CC=CC=C1 BZXGAYPIKOVVIQ-UHFFFAOYSA-N 0.000 claims description 3
- WRICBXYUDUCISR-UHFFFAOYSA-N [3-amino-2,2-bis(nitrooxymethyl)-3-oxopropyl] nitrate Chemical compound [O-][N+](=O)OCC(C(=O)N)(CO[N+]([O-])=O)CO[N+]([O-])=O WRICBXYUDUCISR-UHFFFAOYSA-N 0.000 claims description 3
- MWCIYVGZDBUMBM-UHFFFAOYSA-N [3-hydrazinyl-2,2-bis(nitrooxymethyl)-3-oxopropyl] nitrate Chemical compound [O-][N+](=O)OCC(C(=O)NN)(CO[N+]([O-])=O)CO[N+]([O-])=O MWCIYVGZDBUMBM-UHFFFAOYSA-N 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 230000003511 endothelial effect Effects 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 3
- 239000003071 vasodilator agent Substances 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 claims description 2
- 239000003529 anticholesteremic agent Substances 0.000 claims description 2
- 229940127226 anticholesterol agent Drugs 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 229940030600 antihypertensive agent Drugs 0.000 claims description 2
- 229940127218 antiplatelet drug Drugs 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims description 2
- 239000003218 coronary vasodilator agent Substances 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- ZYIDUENBJBVYGS-UHFFFAOYSA-N ethyl 3-nitrooxy-2,2-bis(nitrooxymethyl)propanoate Chemical compound CCOC(=O)C(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O ZYIDUENBJBVYGS-UHFFFAOYSA-N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 230000036542 oxidative stress Effects 0.000 claims description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 2
- 239000003223 protective agent Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- RLZWEYHQXAPZLP-UHFFFAOYSA-N nitrooxymethyl propanoate Chemical compound CCC(=O)OCO[N+]([O-])=O RLZWEYHQXAPZLP-UHFFFAOYSA-N 0.000 claims 2
- 125000001118 alkylidene group Chemical group 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 229940017219 methyl propionate Drugs 0.000 claims 1
- 239000000810 peripheral vasodilating agent Substances 0.000 claims 1
- 229960002116 peripheral vasodilator Drugs 0.000 claims 1
- OVOHEMOLCOCYQG-UHFFFAOYSA-N propyl 3-nitrooxy-2,2-bis(nitrooxymethyl)propanoate Chemical compound CCCOC(=O)C(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O OVOHEMOLCOCYQG-UHFFFAOYSA-N 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- PJZVKWASWCLGDO-UHFFFAOYSA-N trimethyl 2-nitrooxyethane-1,1,1-tricarboxylate Chemical class COC(=O)C(C(=O)OC)(C(=O)OC)CO[N+]([O-])=O PJZVKWASWCLGDO-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Natural products CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 93
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
- 239000000243 solution Substances 0.000 description 39
- 238000000921 elemental analysis Methods 0.000 description 32
- 229950006286 pentrinitrol Drugs 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 22
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 22
- BRBAEHHXGZRCBK-UHFFFAOYSA-N pentrinitrol Chemical compound [O-][N+](=O)OCC(CO)(CO[N+]([O-])=O)CO[N+]([O-])=O BRBAEHHXGZRCBK-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 239000002253 acid Substances 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 13
- 150000002148 esters Chemical class 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000002585 base Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 150000001408 amides Chemical class 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 159000000000 sodium salts Chemical class 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- WKOZYVCJMAHTPP-UHFFFAOYSA-N 3-nitrooxy-2,2-bis(nitrooxymethyl)propanoic acid Chemical compound [O-][N+](=O)OCC(C(=O)O)(CO[N+]([O-])=O)CO[N+]([O-])=O WKOZYVCJMAHTPP-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- 229910017604 nitric acid Inorganic materials 0.000 description 7
- AGLWDLRTWFJLKX-UHFFFAOYSA-N 4-nitrooxy-3,3-bis(nitrooxymethyl)butanoic acid Chemical compound [O-][N+](=O)OCC(CC(=O)O)(CO[N+]([O-])=O)CO[N+]([O-])=O AGLWDLRTWFJLKX-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- LHSHCLPXMPQXCS-UHFFFAOYSA-N [2,2-bis(hydroxymethyl)-3-nitrooxypropyl] nitrate Chemical compound [O-][N+](=O)OCC(CO)(CO)CO[N+]([O-])=O LHSHCLPXMPQXCS-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- SZQRHWMSOPRRBF-UHFFFAOYSA-N 2-nitrooxyethane-1,1,1-tricarboxylic acid Chemical compound OC(=O)C(C(O)=O)(C(O)=O)CO[N+]([O-])=O SZQRHWMSOPRRBF-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- GFSUITWWXHEIRL-UHFFFAOYSA-N [2-(bromomethyl)-3-nitrooxy-2-(nitrooxymethyl)propyl] nitrate Chemical compound [O-][N+](=O)OCC(CBr)(CO[N+]([O-])=O)CO[N+]([O-])=O GFSUITWWXHEIRL-UHFFFAOYSA-N 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 239000006196 drop Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- CLSWNOZPSMGGNB-UHFFFAOYSA-N 1-bromo-2,2-bis(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)C(O)Br CLSWNOZPSMGGNB-UHFFFAOYSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 229910002651 NO3 Inorganic materials 0.000 description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 229960003827 isosorbide mononitrate Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- NHMNKJDPFMSXDX-UHFFFAOYSA-N 2,2-bis(nitrooxymethyl)propanedioic acid Chemical compound [O-][N+](=O)OCC(C(=O)O)(CO[N+]([O-])=O)C(O)=O NHMNKJDPFMSXDX-UHFFFAOYSA-N 0.000 description 3
- MMHHBAUIJVTLFZ-UHFFFAOYSA-N 2-(bromomethyl)-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)CBr MMHHBAUIJVTLFZ-UHFFFAOYSA-N 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- JFEZYEDPIUIPIJ-UHFFFAOYSA-N 4-hydroxy-3,3-bis(hydroxymethyl)butanenitrile Chemical compound OCC(CO)(CO)CC#N JFEZYEDPIUIPIJ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- OXLSMCKAKKPLCS-UHFFFAOYSA-N methyl 3-nitrooxy-2,2-bis(nitrooxymethyl)propanoate Chemical compound [O-][N+](=O)OCC(C(=O)OC)(CO[N+]([O-])=O)CO[N+]([O-])=O OXLSMCKAKKPLCS-UHFFFAOYSA-N 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 150000002823 nitrates Chemical class 0.000 description 3
- 238000006396 nitration reaction Methods 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- SXYFKXOFMCIXQW-UHFFFAOYSA-N propanedioyl dichloride Chemical compound ClC(=O)CC(Cl)=O SXYFKXOFMCIXQW-UHFFFAOYSA-N 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- CWNLRKOFVNEHRA-UHFFFAOYSA-N (2,2-dicarbonochloridoyl-3-chloro-3-oxopropyl) nitrate Chemical compound [O-][N+](=O)OCC(C(Cl)=O)(C(Cl)=O)C(Cl)=O CWNLRKOFVNEHRA-UHFFFAOYSA-N 0.000 description 2
- KTGAFVGVECOGCK-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)propanedioic acid Chemical compound OCC(CO)(C(O)=O)C(O)=O KTGAFVGVECOGCK-UHFFFAOYSA-N 0.000 description 2
- VEYUMCVDBUYKIX-UHFFFAOYSA-N 2-hydroxyethane-1,1,1-tricarboxylic acid Chemical compound OCC(C(O)=O)(C(O)=O)C(O)=O VEYUMCVDBUYKIX-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- QNGGJBVWSMKPMX-UHFFFAOYSA-N 4-hydroxy-3,3-bis(hydroxymethyl)butanoic acid Chemical compound OCC(CO)(CO)CC(O)=O QNGGJBVWSMKPMX-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 229910015900 BF3 Inorganic materials 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 2
- 206010036600 Premature labour Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- LIUKKSXXAWEQEH-UHFFFAOYSA-N [2-(methoxymethyl)-3-nitrooxy-2-(nitrooxymethyl)propyl] nitrate Chemical compound [O-][N+](=O)OCC(COC)(CO[N+]([O-])=O)CO[N+]([O-])=O LIUKKSXXAWEQEH-UHFFFAOYSA-N 0.000 description 2
- VJSDUDVSWJQRBR-UHFFFAOYSA-N [3-chloro-2,2-bis(nitrooxymethyl)-3-oxopropyl] nitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)C(Cl)=O VJSDUDVSWJQRBR-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000005474 detonation Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002851 endotheliumprotective effect Effects 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 150000002429 hydrazines Chemical class 0.000 description 2
- 238000006698 hydrazinolysis reaction Methods 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007154 intracellular accumulation Effects 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960000201 isosorbide dinitrate Drugs 0.000 description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- RCEXAKLVKUGUFN-UHFFFAOYSA-N methyl 4-nitrooxy-3,3-bis(nitrooxymethyl)butanoate Chemical compound COC(=O)CC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O RCEXAKLVKUGUFN-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000026440 premature labor Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- GFVHBTOOPNJKLV-UHFFFAOYSA-N 1,2-dinitroglycerol Chemical compound [O-][N+](=O)OC(CO)CO[N+]([O-])=O GFVHBTOOPNJKLV-UHFFFAOYSA-N 0.000 description 1
- QYZBMMOLPVKAPU-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl nitrate Chemical compound OCC(CO)O[N+]([O-])=O QYZBMMOLPVKAPU-UHFFFAOYSA-N 0.000 description 1
- ASIGVDLTBLZXNC-UHFFFAOYSA-N 1,3-dinitroglycerol Chemical compound [O-][N+](=O)OCC(O)CO[N+]([O-])=O ASIGVDLTBLZXNC-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- FZKCAHQKNJXICB-UHFFFAOYSA-N 2,1-benzoxazole Chemical compound C1=CC=CC2=CON=C21 FZKCAHQKNJXICB-UHFFFAOYSA-N 0.000 description 1
- HXWLJBVVXXBZCM-UHFFFAOYSA-N 2,3-dihydroxypropyl nitrate Chemical compound OCC(O)CO[N+]([O-])=O HXWLJBVVXXBZCM-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 101000716807 Arabidopsis thaliana Protein SCO1 homolog 1, mitochondrial Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- LJEFFTQVEPVZIW-UHFFFAOYSA-N CCCCOC(C(C)CO[N+]([O-])=O)=O Chemical compound CCCCOC(C(C)CO[N+]([O-])=O)=O LJEFFTQVEPVZIW-UHFFFAOYSA-N 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101001076715 Homo sapiens RNA-binding protein 39 Proteins 0.000 description 1
- 206010020365 Homocystinuria Diseases 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- SKCKOFZKJLZSFA-UHFFFAOYSA-N L-Gulomethylit Natural products CC(O)C(O)C(O)C(O)CO SKCKOFZKJLZSFA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102100023361 SAP domain-containing ribonucleoprotein Human genes 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- ZFIIRBQYUFIXJA-UHFFFAOYSA-N [2-carbonochloridoyl-3-chloro-2-(nitrooxymethyl)-3-oxopropyl] nitrate Chemical compound [O-][N+](=O)OCC(C(Cl)=O)(C(Cl)=O)CO[N+]([O-])=O ZFIIRBQYUFIXJA-UHFFFAOYSA-N 0.000 description 1
- RHVYBZNTBGYKKV-UHFFFAOYSA-N [3-hydroxy-2,2-bis(hydroxymethyl)propyl] nitrate Chemical compound OCC(CO)(CO)CO[N+]([O-])=O RHVYBZNTBGYKKV-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- WIOHBOKEUIHYIC-UHFFFAOYSA-N diethyl 2,2-bis(hydroxymethyl)propanedioate Chemical compound CCOC(=O)C(CO)(CO)C(=O)OCC WIOHBOKEUIHYIC-UHFFFAOYSA-N 0.000 description 1
- QLYJLEIIOFWMBR-UHFFFAOYSA-N diethyl 2,2-bis(nitrooxymethyl)propanedioate Chemical compound CCOC(=O)C(CO[N+]([O-])=O)(CO[N+]([O-])=O)C(=O)OCC QLYJLEIIOFWMBR-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- OFCQLMQFPZNAEU-UHFFFAOYSA-N ethoxymethyl nitrate Chemical compound O([N+](=O)[O-])COCC OFCQLMQFPZNAEU-UHFFFAOYSA-N 0.000 description 1
- KCKXBNDUEKMBFJ-ZETCQYMHSA-N ethyl (2r)-2-[(2,2-dimethyl-3-nitrooxypropanoyl)amino]-3-sulfanylpropanoate Chemical compound CCOC(=O)[C@H](CS)NC(=O)C(C)(C)CO[N+]([O-])=O KCKXBNDUEKMBFJ-ZETCQYMHSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 229940079826 hydrogen sulfite Drugs 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 150000002691 malonic acids Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- AXOQIUPVMQTPRN-UHFFFAOYSA-N nitrooxymethyl butanoate Chemical compound C(CCC)(=O)OCO[N+](=O)[O-] AXOQIUPVMQTPRN-UHFFFAOYSA-N 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- GSKDBLIBBOYOFU-UHFFFAOYSA-N oxadiazol-5-amine Chemical class NC1=CN=NO1 GSKDBLIBBOYOFU-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 150000004672 propanoic acids Chemical class 0.000 description 1
- 229960003402 propatylnitrate Drugs 0.000 description 1
- YZZCJYJBCUJISI-UHFFFAOYSA-N propatylnitrate Chemical compound [O-][N+](=O)OCC(CC)(CO[N+]([O-])=O)CO[N+]([O-])=O YZZCJYJBCUJISI-UHFFFAOYSA-N 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 229960002485 trolnitrate Drugs 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C06—EXPLOSIVES; MATCHES
- C06B—EXPLOSIVES OR THERMIC COMPOSITIONS; MANUFACTURE THEREOF; USE OF SINGLE SUBSTANCES AS EXPLOSIVES
- C06B25/00—Compositions containing a nitrated organic compound
-
- C—CHEMISTRY; METALLURGY
- C06—EXPLOSIVES; MATCHES
- C06B—EXPLOSIVES OR THERMIC COMPOSITIONS; MANUFACTURE THEREOF; USE OF SINGLE SUBSTANCES AS EXPLOSIVES
- C06B25/00—Compositions containing a nitrated organic compound
- C06B25/10—Compositions containing a nitrated organic compound the compound being nitroglycerine
-
- C—CHEMISTRY; METALLURGY
- C06—EXPLOSIVES; MATCHES
- C06B—EXPLOSIVES OR THERMIC COMPOSITIONS; MANUFACTURE THEREOF; USE OF SINGLE SUBSTANCES AS EXPLOSIVES
- C06B25/00—Compositions containing a nitrated organic compound
- C06B25/32—Compositions containing a nitrated organic compound the compound being nitrated pentaerythritol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C203/00—Esters of nitric or nitrous acid
- C07C203/02—Esters of nitric acid
- C07C203/04—Esters of nitric acid having nitrate groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/36—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal
- C07C29/38—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal by reaction with aldehydes or ketones
- C07C29/42—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal by reaction with aldehydes or ketones with compounds containing triple carbon-to-carbon bonds, e.g. with metal-alkynes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
Definitions
- the invention presented here relates to new derivatives of pentaerythritol, their preparation and use, which can be used in particular as pharmaceuticals, and intermediates for the synthesis thereof.
- GTN glycerol trinitrate
- PETN pentaerythrityl tetranitrate
- Patent 2,370,437 Isosorbide-5-mononitrate (ISMN) (DE-OS-22 21 080, DE-OS-27 51 934, DE-OS-30 28 873, DE-PS-29 03 927, DE-OS-31 02 947 , DE-OS-31 24 410, EP-Al-045 076, EP-Al-057 847, EP-Al-059 664, EP-Al-064 194, EP-Al-067 964, EP-Al-143 507 , U.S. Patent 3,886, U.S. Patent 4,065,488, U.S. 4,417,065, U.S. 4,431,829), Isosorbide Dinitrate (ISDN) (L.
- ISMN Isosorbide-5-mononitrate
- ISDN Isosorbide Dinitrate
- Comparable and improved pharmacological activity when used in the above-mentioned indication areas have organic “nitrates” of a newer type such as, for example, SPM 3672 (N- [3-nitratopivaloyl] -L-cysteine ethyl ester) (US Pat. No. 5,284,872) and its derivatives or 1, 4-dihydropyridine derivatives (WO-Al-92/02503).
- endothelial protective agents DE-Al-44 10 997
- agents against pathologically increased intraocular pressure WO-Al-95/13812
- agents against dysmenorrhea dysfunctional uterine bleeding, premature labor or after-pains by reducing uterine contractility
- WO-Al-95/13802 as a remedy for climacteric symptoms
- WO-Al -95 / 13800 a remedy for erectile dysfunction
- the previously known organic nitric acid esters have a number of therapeutic disadvantages.
- the so-called nitrate tolerance can be observed, i.e. the decrease in the nitrate effect with high doses or with the application of long-acting nitric acid esters.
- There are also side effects such as headache, dizziness, nausea, weakness, skin redness and The risk of a greater drop in blood pressure is demonstrated by reflex tachycardia (Mutschier, Arzneiffenantsen, Academic Members Verlagsgesellschaft mbH, Stuttgart, 1991)
- PETN as an active ingredient has a number of outstanding properties, in particular little to no occurrence of the above-mentioned side effects, which favor a preferred use of this compound as a pharmaceutical justify other organic nitric acid esters (series "Pentaerythrityltetranitrat", Dr Dietrich Steinkopff Verlag, Darmstadt, 1994 to 1996)
- the galenic processing of the organic nitric acid esters into pharmaceutical preparations for the treatment of angina pecto ⁇ s or ischemic heart disease is generally known. It is carried out according to the procedures and rules generally familiar to the pharmaceutical expert, the choice of the technologies to be used and the galenic auxiliaries used being primarily based on the active ingredient to be processed Questions regarding its chemical-physical properties of the chosen form of administration, the desired duration of action and the avoidance of drug-auxiliary incompatibilities are of particular importance.
- the platelet activation factor (platelet activation factor), an l-alkyl-2-acetvl ether analog of the phosphatidylcho ns of the formula
- H C-CO-0-CH (CH 2 -O- (CH 2 ) 15 -CH.) - CH 2 -0-P0 2 -0-CH 2 -CH 2 -N (CH,), is capable of extremely low concentration of 0.1 nM in the blood to trigger platelet aggregation and vasodilation (Stryer, Biochemie, Spektrum dermaschineen Heidelberg, 1990)
- R 1 , R 2 , R 1 are identical or different from one another CH 2 -ONO 2 , CH 2 -OR 4 or R 5 , but at least one of the substituents R 1 to R 3 is R 5 , R 4 is H or C to C 6 -alkanoyl,
- R 5 COR ⁇ , R 6 OH, OR 7 , NH 2 , NHR 7 , NR 7 2 , N + R 7 3 X " , NR 8 , NR 9 R 10 , NR n R 12 or NH-NH 2 ,
- R 7 straight-chain or branched Cj- to C ⁇ -alkyl, straight-chain or branched d- to C 6 -alkenyl, aryl, aralkyl, hetaryl or hetaralkyl, R 8 C ⁇ - to C ⁇ -al ylidene, R 9 , R 10 from each other different R 7 ,
- R 1 1 , R 12 are the same or different, NR 7 2 , N + R 7 3 X " , NR 8 and
- X represents a halogen or a group capable of forming anions, and their therapeutically contractual salts
- R 6 are OH, OR 7 , NH 2 , NHR 7 , NR 7 2 or N + R 7 3 X " , namely in particular the esters and mixed esters, amides, half-amides, amide esters and ammonium salts
- Further preferred embodiments are compounds with one, two and three hydrophilic groups. This relates in particular to the metal and ammonium salts, esters, amides and hydrazides of carboxylic acids.
- the compounds of the formulas are particularly preferred
- nitric acid esters of pentaerythritol serve as starting compounds, with respect to their representation expressly referring to the process of partial denitration of pentaerythrityl tetranitrate using hydrazine (Simecek, Coll. Czech. Chem. Comm. 27 (1962), 363 and US Pat. No. 3,408,383 )
- Another method is the nitration of pentaerythritol to trinitrate, followed by its hydrazinolysis to pentaerythrityldi and mononitrate and by the chromatographic separation of the resulting mixture.
- 2,2-bis (hydroxymethyl) malonic acid (Gault, Roesch, CR Hebd. Seances Acad.
- Suitable for this purpose are in particular straight-chain and branched primary, secondary and tertiary C ⁇ -C f, alkanols, -alkenols and aryl, hetaryl, aralkyl, Hetaralkylalkohole.
- the homologous acid amides, half-amides or hydrazides are obtained by reacting the acid halides and esters mentioned with NH 3 , primary and secondary amines or hydrazine or 1-substituted hydrazines.
- Primary and secondary aliphatic, aromatic and heteroaromatic amines or hydrazine and 1 -substituted are suitable for this Hydrazine.
- a further embodiment of the invention are the compounds of the general formula XIV,
- R 13 is a group of the formula XV
- the compounds of formula XIV are in particular obtained from the compounds of formulas VIII to XIII e.g. 3-Nitryloxy-2,2-bis (nitryloxymethyl) propionic acid (Tri-PS), 2,2-bis (nitryloxymethyl) malonic acid (Bis-MS) or 2-carboxy-2-nitryloxymethylmalonic acid (CN-MS) by reaction with Pentaerythritol derivatives of the formula XV 1,
- Derivatives of the compounds of the formulas VIII to XIII such as, for example, of tri- PS, Bis-MS, CN-MS or XV 1 can be used as starting compounds for the synthesis of the compounds XIV, the functional groups of which, as suitable leaving groups, enable the person skilled in the art to access the target compounds via esterification reactions.
- the reaction is carried out according to the generally known methods and processes for the preparation of esters
- a further embodiment of the invention are the compounds of the general formula XVI,
- R 14 , R 15 , R 1 are identical or different from one another H, OR 19 , ONO 2 , OR 17 or R 18 , R 17 COR 19 or R 23 ,
- R 19 H straight-chain or branched d- to C f , -alkyl, R 20 straight-chain or branched C to Cc-alkyl-R 21 ,
- R 22 R 19 aryl or NR , 9 2 ,
- R 23 is a 3- or 5-carbonyl radical of a 1,4-dihydropyridine-3,5-dicarboxylic acid optionally substituted in the 2, 4 and / or 6-position, a 1-substituted pyrrolidine-2-carbonyl radical, an N-carbonyl radical of a substituted one Sydnonimins, a residue -CO-CH (NHCOR 19 ) -CR 19 2 -S-NO, a residue -CO-CH (NH 2 ) -CR 19 2 -S-NO or a residue -NH-CH (COOR 19 ) -CR 19 2 -S-NO and X represent a halogen or a group capable of forming anions, and also their therapeutically acceptable salts, the combinations
- R 18 are COOR 19 , in particular the compounds of the formula XVII,
- R 19 is H, methyl, ethyl, Na or K, and the compounds of the formula XVIII,
- R 19 is methyl or ethyl
- Nitric acid to 3-nitryloxy-2,2-bis (nitryloxymethyl) propyl bromide D.E. Elrik et al., Am.Soc. 76 [1954] 1374) followed by its grignardation and reaction with carbon dioxide.
- the 2,2-bis (hydroxymethyl) malonic acid diethyl ester (Gault, Roesch, CR Hebd Seances Acad.
- methyl-2,2 is used to prepare the 2,2-bis (nitryloxymethyl) malonic acid diethyl ester , 2-tris (nitryloxymethyl) ethyl ether is obtained after the ether synthesis according to WILLIAMSON or by reacting pentaerythrityl trinitrate with ethereal diazomethane solution in the presence of catalytic amounts of boron trifluoride.
- a further embodiment is represented by the compounds in which the 3- or 5-carbonyl radical of a 1,4-dihydropyridine-3,5-dicarboxylic acid optionally substituted in the 2, 4 and / or 6-position is replaced by a radical of unsymmetrical esters which are 1- substituted pyrrolidine-2-carbonyl radical by a radical or the N-carbonyl radical of a substituted sydnonimine are formed by a radical, which are known to the person skilled in the art that they belong to the substance classes of the calcium antagonists, the ACE inhibitors or the coronary dilators
- R 26 is H, represent a further embodiment of the invention, the compounds of the formula XX in particular compound of the formula XXI,
- An additional embodiment of the present invention are the compounds of the general formula XXII,
- R 27 is independently NO 2 or R 17 to R 23 , each with the meaning defined above, and n is an integer from 0 to 10, preferably from 0 to 4.
- the method of partial denitration of bis [2,2,2-tris (nitryloxymethyl)] ethyl ether using hydrazine is used, for example, to prepare the symmetrical bis (2,2-bis (nitryloxymethyl) -2-hydroxymethyl) ethyl ether.
- various end products are obtained either as free acid or base, base or acid addition salt or betaine, each of which is within the scope of the invention.
- Acidic, basic, neutral or mixed salts and hydrates can be obtained in this way.
- the respective salts can be converted into the free acid or base in a manner known per se using appropriate means or by ion exchange.
- the free acids or bases obtained can form salts with organic or inorganic bases or acids.
- base addition salts above all bases used which form suitable therapeutically acceptable salts.
- Such bases are, for example, hydroxides or hydrides of the alkali and alkaline earth metals, ammonia, amines and hydrazines or guanidines.
- Such acids are, for example, hydrogen halide, sulfone, phosphorus , Nitric and perchloric acid, furthermore aliphatic, acyclic, aromatic, heterocyclic carbon or sulfonic acids such as formic, acetic, propionic, amber, glycolic, lactic, apple, wine, lemon, gluconic, sugar -, Glucuron-, Ascorbin-, Maiein-, Hydroxymalein-, Pyruv-, Phenylacetic-, Benzoe-, p-Aminobenzoe-, Anthranil-, p-Hydroxybenzoe-, Salicyl-, Acetylsalicyl-, p-Aminahacyl-, Embon- Methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, ethylene sulfonic, halobenzenesulfonic, toluenesulfonic, naphthyl
- salts of the new compounds can serve as agents for the purification of the free acids or bases obtained.
- Salts of the acids or bases can be formed and separated from solutions, and then the free acid or base can be obtained from a new salt solution in a purer state. Because of the relationship between the new compounds in their free form and their salts, the salts are within the Scope of the invention.
- the new compounds can be present as optical isomers or racemates, or if they contain at least two asymmetric centers, they can be present as an isomer mixture (racemate mixture).
- the isomer mixtures (racemate mixtures) obtained can be obtained using the
- Racemates obtained can be prepared according to known methods Methods are separated, such as by conversion from an optically active solvent, by using microorganisms, by reaction with optically active agents to form compounds which can be separated, by separation on the basis of the different solubilities of the diastereoisomers.
- Suitable optically active agents are the L and D forms of wine, di-o-tolylwem, apple, almond, glucon,
- the compounds according to the invention can be used themselves or as part of a galenical preparation, as a single active ingredient, in combination with one another or with known cardiovascular therapies, for example ACE inhibitors, antiatherosclerotics, antihypertensives, beta-blockers, cholesterol-lowering agents, diuretics, calcium channel blockers, coronary dilatators, lipid peptides, lipid peptides Vasodilators, platelet aggregation inhibitors or other substances, also used as cardiovascular therapeutics, combined, can be used for their clinical use.
- cardiovascular therapies for example ACE inhibitors, antiatherosclerotics, antihypertensives, beta-blockers, cholesterol-lowering agents, diuretics, calcium channel blockers, coronary dilatators, lipid peptides, lipid peptides Vasodilators, platelet aggregation inhibitors or other substances, also used as cardiovascular therapeutics, combined, can be used for their clinical use.
- the preparation of galenical preparations is carried out according to
- the pharmaceutical form in question should be designed in such a way that it can be achieved therapeutic plasma level contains the respective active ingredient in an amount which makes it possible to distribute the daily dose to 1 to 2 in the case of release-controlled systems and to up to 10 individual doses in the case of other dosage forms. Continuous administration by means of long-term infusion is also suitable. In general, endothelial protection effects are achieved Long-term therapeutic blood levels should be aimed for.
- the named compounds can be administered primarily orally, intravenously, parenterally, sublingually or transdermally.
- the respective pharmaceutical preparation is preferably in liquid form er or solid form provided. Suitable for this are solutions, in particular for the preparation of drops, injections, aerosol sprays or powder inhalers, furthermore suspensions, emulsions, syrups, tablets, film-coated tablets, dragees, capsules, pellets, powders, lozenges, implants, supplements, creams, Gels, ointments, plasters or other transdermal systems
- the pharmaceutical preparations contain customary galenically usable, organic or inorganic carriers and auxiliaries, which should themselves be chemically indifferent to the respective active ingredients.
- Chemical de ⁇ vatation when applied to carrier materials is also included, this concerns in particular the formation of adducts with sugar derivatives such as croscarmeloses or cyclodextins
- Suitable pharmaceutical auxiliaries are water. Salt solutions, alcohols, vegetable oils, polyethylene glycols, gelatin, lactose, amvloses, magnesium stearate, talc, highly disperse silicon dioxide, paraffin, fatty acid mono- and diglyce ⁇ de, cellulose derivatives, polyvinyl pyrrone and the like.
- the preparation can be sterilized and if necessary with auxiliary substances such as fillers, binders, lubricants, mold release agents, lubricants, disintegrants, moisturizers, adsorbents or counter-explosives, preservatives, stabilizers, emulsifiers, solubilizers, salts for influencing the osmotic pressure, buffer solutions, coloring, fragrance Aroma or sweeteners may be added
- auxiliary substances such as fillers, binders, lubricants, mold release agents, lubricants, disintegrants, moisturizers, adsorbents or counter-explosives, preservatives, stabilizers, emulsifiers, solubilizers, salts for influencing the osmotic pressure, buffer solutions, coloring, fragrance Aroma or sweeteners may be added
- auxiliary substances such as fillers, binders, lubricants, mold release agents, lubricants, disintegrants, moisturizers, adsorbents or counter-explosives
- the compounds according to the invention surprisingly have the desired properties.
- they are distinguished in part by an optimized NO liberation, for example by their differentiated content of reductively or oxidatively biotransforming NO precursor groups or by an improved or increased multiphase NO Liberation and, depending on the intended use, increased lipophilicity or hydrophilicity, good bioavailability, increased cGMP accumulation, as well as reduced pharmacodynamic preload, reduced increase in endothein in plasma, pronounced inhibition of platelet aggregation by platelet-active groups and endothelium-protective effect
- the presented invention thus opens up improved and considerably expanded therapeutic options, pathological situations such as heart and vascular diseases, in particular coronary heart disease, vascular stenoses and circulatory disorders of the peripheral arteries, hypertension, micro- and macroangiopathies in the context of diabetes mellitus, atherosclerosis, oxidative stress states in vessels and tissues and the resulting complications, erectile dysfunction, increased intraocular pressure, dysmenorrhea, dysfunctional uterine bleeding, dysfunction of uterine contractility such as premature labor pains, symptoms of cacti or incontinence
- Example 1 Pentaeryth ⁇ tylt ⁇ nitrat 158 g (0.5 mol) of Pentaerythrityltetranitrat (PETN) are dissolved in a mixture of 300 ml of dioxane and 300 ml of ethanol with boiling and for 1 hour in portions with different amounts of aqueous hydrazine hydrate solution (1, 5-4 mol) The reaction mixture is then heated to boiling under reflux for a further 2.5 hours. The solvents are evaporated off at 15 mm Hg and the residue is shaken out several times with 100 ml portions of water, as required, until the volume of the oil layer no longer decreases when shaken out The water extracts (A) are collected and the remaining oily layer is dissolved in twice the volume of ethanol.
- PETN Pentaeryth ⁇ tylt ⁇ nitrat
- the filtrate is evaporated at 15 mm Hg ethanol.
- the viscous, oily residue consists of the crude pentaerythritol itrat (PET ⁇ N), corresponds to nitrogen content
- Pentaeryth ⁇ tyldinitrat and Pentaeryth ⁇ tylmononitrat The combined aqueous extracts A according to Example 1 are shaken three times with ether and evaporated from the ether layer separated from the aqueous layer B after drying over anhydrous Na 2 SO 4.
- the very viscous, oily evaporation pressure consists of crude pentaerythritol (NED) dinitrate aqueous portion B, which in addition to the pentaerytonic mononitrate (PEMN) and pentaerythric denitization products, mainly hydrazine nitinate, is successively acidified with 2N H 2 SÜ until gas evolution ceases (N 2 , N 2 O, NO, N 3 H), then at 20 mm Hg until the onset of separation of solid products, concentrated and etherified.
- the crystalline substance remaining after evaporation of the ether from F p 62 ° C is crude PEMN. Then it is washed with cold chloroform and converted from chloroform.
- F p 79 ° C (HCC1 3 )
- PETriN is represented by nitration of pentaerythritol with HN0 3 (95%) in the presence of urea
- PEDN and PEMN are prepared from PETriN by hydrazinolysis (4 mol NH 2 NH 2 (50%)) followed by separation of the 1 1 mixture by column chromatography
- a clay cell is hung in a beaker as a diaphragm.
- 25% H 2 SO 4 serves as the catholyte
- the cathode consists of lead, a lead plate as the anode is immersed in the anolyte solution consisting of
- Tri-PS 1.0 g (0.0032 mol) of Tri-PS are dissolved in 30 ml of water. The solution is aqueous with 1%
- Tri-PSCl oily 3-nitryloxy-2,2-bis (nitryloxymethyl) propionic acid chloride
- Carboxy-2-nitryloxymethylmalonic acid (CN-MS) is obtained analogously to embodiment 10.
- bis-MSDCl 2,2-bis (n ⁇ tryloxymethyl) malonic acid dichloride
- thionyl chloride double the amount of thionyl chloride and 2-chlorocarbonyl-2-nitryloxymethylmalonic acid dichloride
- Tri-PS 1 g (3.5 mmol) of Tri-PS is mixed with 10.5 mmol of ethanol, 20 mg of toluenesulfonic acid and 30 ml of chloroform and heated under reflux for 12 hours on a water separator
- Chloroform phase is washed with aqueous bicarbonate solution and with water that
- 3-Nitryloxy-2,2-bis (nitryloxymethyl) propionic acid ethyl ester (tri-PS ethyl ester) is obtained as a colorless 01 yield of 85% elemental analysis (C corresponds to H corresponds to N corresponds to)
- T ⁇ -PSCl 1 g (3.4 mmol) of T ⁇ -PSCl is dissolved in 25 ml of dioxane and concentrated with excess Ammonia solution added. After 30 minutes, pour into 100 ml of ice water and weakly acidify with dilute hydrochloric acid. The oily, deposited 2,2-bis (nitryloxymethyl) -3-nitryloxypropaneureamide (Tri-PS amide) is purified by column chromatography. Yield 65% elemental analysis - (C corresponds to H corresponds to N corresponds to)
- Tri-PS Tri-PS 7 mmol are mixed with 1 ml of thionyl chloride and 1 drop of dry DMF and stirred for 20 minutes at room temperature with exclusion of moisture. Then 3 ml of cold concentrated NH 3 solution are added to the reaction mixture and the solution is left on
- Embodiments 23 and 26 represented by doubling or tripling the reagents a) Bis-MS-diamid
- reaction mixture is gasified for a further 120 min at -5 ° C. and then poured into ice water.
- the precipitated product is filtered off, washed with water or 5% sodium hydrogen carbonate solution and then recrystallized from ethanol. Yield 91%
- Tri-BS Tri-BS are mixed with a 5-fold excess of thionyl chloride and at
- Example 38 Methyl 2,2,2-tris (nitryloxymethyl) ethyl ether 0.025 mol sodium and 0.12 mol abs. Methanol is used to prepare the methanolate solution. 0.02 mol of 3-nitryloxy-2,2-bis (nitryloxymethyl) propyl bromide is added and the mixture is heated under reflux for 5 hours with exclusion of moisture and stirring. The reaction mixture is cooled to 5 times the amount Water was added, the ether (Me-PETriN ether) was separated off, washed again with water, dried and purified by column chromatography. Yield 75%
- Methyl 2,2,2-tris (nitryloxymethyl) ethyl ether 0.02 mol PETriN are dissolved in methanol / water (10 l) with the addition of catalytic amounts of boron trifluoride and mixed with as much ethereal diazomethane solution at room temperature with stirring until a weak yellow color persists or until no more N 2 development
- the solvent is distilled off and the residue is taken up with diethyl ether. Then the mixture is washed with dilute sodium hydroxide solution and water, dried and, after the solvent has been distilled off, the crude product (Me-PETriN ether) is purified by column chromatography. Yield 49% elemental analysis (C corresponds to H corresponds to N corresponds to N) )
- Example 41 Bis- [2,2,2-tris (nitryloxymethyl)] ethyl ether
- a typical tablet has the following composition:
- Active ingredient x mg a) PETriNAc 20 mg b) PETriNAc 80 mg cc)) P PEETTrriiNNAAcc 160 mg d) PEDNdAc 20 mg e) PETriN 7 3 H 2 O 20 mg
- a pump spray contains: a) Tri-PS 0.05% by weight / ci in water b) Tri-PS 0.3% by weight in water c) Tri-PS 5% by weight in water d) Tri -PS 10% by weight in water e) Tri-PS sodium salt 0.3% by weight in water f) Tri-PS sodium salt 5% by weight in water g) Tri-PS potassium salt 0.3% by weight in water h) Tri-PS potassium salt 5% by weight in water i) Tri-BS sodium salt 0.3% by weight in water j) Tri-BS sodium salt 5% by weight in water k) Tri-BS potassium salt 0.3% by weight in water
- the detonation properties of the compounds are determined by the known methods for determining the expansion performance, the detonation speed, the impact pressure and the initiation (Ulimanns Encyklopadie der technical chemistry, Vol 16, 3 Auf!, Urban & Schwarzenberg, Kunststoff-Berlin, 1965)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19641667 | 1996-10-10 | ||
DE19641667A DE19641667A1 (de) | 1996-10-10 | 1996-10-10 | Neue Ester der Salpetersäure sowie deren Herstellung und Verwendung |
DE19652345 | 1996-12-17 | ||
DE1996152345 DE19652345A1 (de) | 1996-12-17 | 1996-12-17 | Neue Salpetersäureester, deren Herstellung und Verwendung |
DE19726812 | 1997-06-25 | ||
DE19726812A DE19726812A1 (de) | 1997-06-25 | 1997-06-25 | Neue Derivate des Pentaerythrits, deren Herstellung und Verwendung sowie Intermediate zur Synthese derselben |
PCT/DE1997/002328 WO1998015521A1 (de) | 1996-10-10 | 1997-10-10 | Neue derivate des pentaerythrits, deren herstellung und verwendung sowie intermediate zur synthese derselben |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1009730A1 true EP1009730A1 (de) | 2000-06-21 |
Family
ID=27216719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97945736A Withdrawn EP1009730A1 (de) | 1996-10-10 | 1997-10-10 | Neue derivate des pentaerythrits, deren herstellung und verwendung sowie intermediate zur synthese derselben |
Country Status (20)
Country | Link |
---|---|
US (1) | US6180664B1 (zh) |
EP (1) | EP1009730A1 (zh) |
JP (1) | JP2001501627A (zh) |
CN (1) | CN1239944A (zh) |
AU (1) | AU736253B2 (zh) |
BG (1) | BG103303A (zh) |
BR (1) | BR9715045A (zh) |
CA (1) | CA2267129A1 (zh) |
CZ (1) | CZ9901223A3 (zh) |
EA (1) | EA001959B1 (zh) |
EE (1) | EE9900116A (zh) |
HR (1) | HRP970546A2 (zh) |
IL (1) | IL129339A0 (zh) |
NO (1) | NO991622L (zh) |
NZ (1) | NZ335057A (zh) |
PL (1) | PL332594A1 (zh) |
SK (1) | SK43499A3 (zh) |
TR (1) | TR199900791T2 (zh) |
WO (1) | WO1998015521A1 (zh) |
YU (1) | YU17999A (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0988282A2 (de) | 1997-06-11 | 2000-03-29 | Isis Pharma Gmbh | Neue pentaerythritderivate, deren herstellung und verwendung sowie intermediate zur synthese derselben |
WO1999067430A2 (de) * | 1998-06-24 | 1999-12-29 | Alpharma-Isis Gmbh & Co. Kg | Analytische substrate und antioxidative mittel |
DE19950483A1 (de) * | 1999-10-19 | 2001-05-10 | Isis Pharma Gmbh | Verfahren zur Herstellung von 3-Nitryloxy-2,2-bis(nitryloxymethyl)-propanal |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20050065184A1 (en) * | 2003-08-29 | 2005-03-24 | Aaipharma Inc. | Method of reducing the risk of oxidative stress |
CN103848704A (zh) * | 2012-11-30 | 2014-06-11 | 陕西省汉阴华能新材料研究有限公司 | 回收油的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1883045A (en) * | 1931-11-20 | 1932-10-18 | Du Pont | Explosive composition |
GB442850A (en) * | 1934-05-14 | 1936-02-17 | Bombrini Parodi Delfino | Improvements in and relating to the production of explosives |
US2389228A (en) * | 1943-04-14 | 1945-11-20 | Trojan Powder Co | Preparation of tripentaerythritol octanitrate |
NL110701C (zh) * | 1960-03-14 | |||
US3419571A (en) * | 1966-04-06 | 1968-12-31 | Warner Lambert Pharmaceutical | Method for relieving coronary insufficiency |
US4394329A (en) * | 1979-06-26 | 1983-07-19 | Thiokol Corporation | 2-Hydroxymethyl-1,3-propanediol nitrate ester |
CS221031B1 (en) * | 1981-12-28 | 1983-04-29 | Svatopluk ZEMAN | Method of making the nitrates,derivatives of the trimethylmethane |
-
1997
- 1997-10-10 CA CA002267129A patent/CA2267129A1/en not_active Abandoned
- 1997-10-10 CZ CZ19991223A patent/CZ9901223A3/cs unknown
- 1997-10-10 TR TR1999/00791T patent/TR199900791T2/xx unknown
- 1997-10-10 IL IL12933997A patent/IL129339A0/xx unknown
- 1997-10-10 AU AU51155/98A patent/AU736253B2/en not_active Ceased
- 1997-10-10 EE EEP199900116A patent/EE9900116A/xx unknown
- 1997-10-10 JP JP10517083A patent/JP2001501627A/ja active Pending
- 1997-10-10 HR HR19726812.9A patent/HRP970546A2/hr not_active Application Discontinuation
- 1997-10-10 WO PCT/DE1997/002328 patent/WO1998015521A1/de not_active Application Discontinuation
- 1997-10-10 NZ NZ335057A patent/NZ335057A/xx unknown
- 1997-10-10 CN CN97180509A patent/CN1239944A/zh active Pending
- 1997-10-10 EA EA199900363A patent/EA001959B1/ru not_active IP Right Cessation
- 1997-10-10 EP EP97945736A patent/EP1009730A1/de not_active Withdrawn
- 1997-10-10 US US09/269,969 patent/US6180664B1/en not_active Expired - Fee Related
- 1997-10-10 SK SK434-99A patent/SK43499A3/sk unknown
- 1997-10-10 BR BR9715045-2A patent/BR9715045A/pt not_active IP Right Cessation
- 1997-10-10 PL PL97332594A patent/PL332594A1/xx unknown
- 1997-10-10 YU YU17999A patent/YU17999A/sh unknown
-
1999
- 1999-04-02 BG BG103303A patent/BG103303A/bg unknown
- 1999-04-06 NO NO991622A patent/NO991622L/no not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9815521A1 * |
Also Published As
Publication number | Publication date |
---|---|
BR9715045A (pt) | 2001-01-16 |
YU17999A (sh) | 2002-03-18 |
EE9900116A (et) | 1999-10-15 |
NO991622D0 (no) | 1999-04-06 |
AU736253B2 (en) | 2001-07-26 |
US6180664B1 (en) | 2001-01-30 |
NO991622L (no) | 1999-06-04 |
JP2001501627A (ja) | 2001-02-06 |
HRP970546A2 (en) | 1998-08-31 |
SK43499A3 (en) | 2000-02-14 |
PL332594A1 (en) | 1999-09-27 |
BG103303A (bg) | 2000-01-31 |
CN1239944A (zh) | 1999-12-29 |
CA2267129A1 (en) | 1998-04-16 |
WO1998015521A1 (de) | 1998-04-16 |
TR199900791T2 (xx) | 1999-07-21 |
IL129339A0 (en) | 2000-02-17 |
CZ9901223A3 (cs) | 2002-10-16 |
EA199900363A1 (ru) | 1999-12-29 |
NZ335057A (en) | 2000-09-29 |
AU5115598A (en) | 1998-05-05 |
EA001959B1 (ru) | 2001-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60223923T2 (de) | Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke | |
DE2434911A1 (de) | Phenylaethylamin-derivate | |
EP0271795A2 (de) | Octahydro-10-oxo-6H-pyridazo [1,2-a] [1,2] diazepin-Derivate, Zwischenprodukte und Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel | |
EP0046707A1 (fr) | Dérivés de l'acide amino-4 butyrique et les médicaments, actifs notamment sur le système nerveux central, en contenant | |
WO1998015521A1 (de) | Neue derivate des pentaerythrits, deren herstellung und verwendung sowie intermediate zur synthese derselben | |
EP0001144B1 (de) | N-Substituierte 2-Hydrazono-Propionsäure-Derivate, Verfahren zur Herstellung derselben und Arzneimittel, die diese enthalten | |
CH617183A5 (zh) | ||
DE19826781A1 (de) | Neue Pentaerythritderivate, deren Herstellung und Verwendung sowie Intermediate zur Synthese derselben | |
EP0086453B1 (de) | Thiazaspiranderivate, Verfahren zu ihrer Herstellung und Arzneimittel | |
EP0007347B1 (de) | Lipidsenkende Alkylenglykolderivate und Verfahren zu ihrer Herstellung | |
DE1620747C3 (de) | Carbothiamin sowie dessen nichttoxische organische oder anorganische Säureadditionssalze sowie Verfahren zur Herstellung dieser Verbindungen | |
DE2345060C3 (de) | 1,2-Dialkylketonglycerin-3-phosphatide und Verfahren zu deren Herstellung | |
EP0002219B1 (de) | Arzneimittel mit schwefelhaltigen Estern und Verfahren zu ihrer Herstellung | |
DE19726812A1 (de) | Neue Derivate des Pentaerythrits, deren Herstellung und Verwendung sowie Intermediate zur Synthese derselben | |
DE19641667A1 (de) | Neue Ester der Salpetersäure sowie deren Herstellung und Verwendung | |
DE2004301A1 (de) | Phenylserinderivate | |
DE19652345A1 (de) | Neue Salpetersäureester, deren Herstellung und Verwendung | |
DE19827981A1 (de) | Analytische Substrate | |
DE19830006A1 (de) | Pentaerythritolderivate und Intermediate zu deren Herstellung | |
US2979525A (en) | New crystalline pantothenic acid ester and process for the production thereof | |
DE2710807C2 (de) | Benzylamino-alkancarboxamide, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
WO1999067430A2 (de) | Analytische substrate und antioxidative mittel | |
EP0003456A1 (fr) | Dérivés d'amino-3-cardénolides, procédé pour leur préparation, et médicaments les contenant | |
DE2753768A1 (de) | Antiphologistisch wirkende arzneimittel | |
EP1023307A1 (en) | Novel nitric esters of pentaerythritol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990721 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 19990721;LT PAYMENT 19990721;LV PAYMENT 19990721;RO PAYMENT 19990721;SI PAYMENT 19990721 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 20020226 |